Citius Pharmaceuticals, Inc. reported its fiscal second quarter 2025 financial results, showing a net loss of $11.5 million for the quarter ended March 31, 2025, compared to a net loss of $8.5 million for the same period in 2024. This increase in net loss was primarily attributed to a $2.6 million decrease in other income, alongside higher general and administrative expenses and research and development expenses. The company's R&D expenses for the quarter were $3.8 million, slightly up from $3.6 million in the previous year, mainly due to costs associated with LYMPHIR. For the six months ended March 31, 2025, R&D expenses totaled $5.9 million, down from $6.3 million in the prior year. Citius Pharmaceuticals also reported receiving $6 million in net proceeds from equity issuance during the six months ended March 31, 2025. An additional $1.735 million was secured from a direct offering on April 2, 2025. As of March 31, 2025, the company held $26,410 in cash and cash equivalents, with 8,760,649 common shares outstanding, excluding the recent financing. The company indicated the need to secure further capital to sustain operations beyond May 2025. In operational updates, Citius is focusing on the planned launch of its first FDA-approved product, LYMPHIR, through Citius Oncology. The company is actively seeking strategic partnerships and securing necessary financing to advance its launch strategy. Citius Oncology has retained Jefferies LLC as its exclusive financial advisor to explore strategic alternatives to maximize shareholder value.